GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » EV-to-EBITDA

Bangkok Genomics Innovation PCL (BKK:BKGI) EV-to-EBITDA : 93.04 (As of Jun. 09, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bangkok Genomics Innovation PCL's enterprise value is ฿1,315.51 Mil. Bangkok Genomics Innovation PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ฿14.14 Mil. Therefore, Bangkok Genomics Innovation PCL's EV-to-EBITDA for today is 93.04.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's EV-to-EBITDA or its related term are showing as below:

BKK:BKGI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 24.49   Med: 29.46   Max: 97.28
Current: 93.05

During the past 5 years, the highest EV-to-EBITDA of Bangkok Genomics Innovation PCL was 97.28. The lowest was 24.49. And the median was 29.46.

BKK:BKGI's EV-to-EBITDA is ranked worse than
96.3% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.15 vs BKK:BKGI: 93.05

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-09), Bangkok Genomics Innovation PCL's stock price is ฿2.82. Bangkok Genomics Innovation PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ฿0.020. Therefore, Bangkok Genomics Innovation PCL's PE Ratio for today is 141.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Bangkok Genomics Innovation PCL EV-to-EBITDA Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL EV-to-EBITDA Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - - -

Bangkok Genomics Innovation PCL Quarterly Data
Dec20 Dec21 Mar22 Dec22 Mar23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial - - - - 116.81

Competitive Comparison of Bangkok Genomics Innovation PCL's EV-to-EBITDA

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bangkok Genomics Innovation PCL's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's EV-to-EBITDA falls into.



Bangkok Genomics Innovation PCL EV-to-EBITDA Calculation

Bangkok Genomics Innovation PCL's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1315.506/14.139
=93.04

Bangkok Genomics Innovation PCL's current Enterprise Value is ฿1,315.51 Mil.
Bangkok Genomics Innovation PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿14.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bangkok Genomics Innovation PCL  (BKK:BKGI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Bangkok Genomics Innovation PCL's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.82/0.020
=141.00

Bangkok Genomics Innovation PCL's share price for today is ฿2.82.
Bangkok Genomics Innovation PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Bangkok Genomics Innovation PCL EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).

Bangkok Genomics Innovation PCL (BKK:BKGI) Headlines